Editorial: Anemia management with erythropoiesis-stimulating agents: A risk-benefit update

Oncologist

Volumn 13, Issue SUPPL. 3, 2008, Pages 1-3

  Aapro, Matti S ^a,b  

^a Multidisciplinary Oncology Institute   (Switzerland)

^b CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Anemia; Erythropoiesis stimulating agents; Erythropoietin receptors; Risk benefit

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; EDITORIAL; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; NEOPLASM; NOTE; RISK ASSESSMENT; THROMBOEMBOLISM;

ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; NEOPLASMS; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 54049110046     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.13-S3-1     Document Type: Editorial

References (29)

1. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancerpatients. Eur J Cancer 2004;40:2293-2306.
2. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoi-etins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714.
3. Seidenfeld J, PiperM, Bohlius J et al. Comparative Effectiveness of Epoe-tin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. Comparative Effectiveness Review No. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Evidence-based Practice Center under Contract No. 290-02-0026.) Rockville, MD: Agency for Healthcare Research and Quality. May 2006. Available at http://effectivehealthcare.ahrq.gov/ repFiles/EPO%20Final. pdf. Accessed April 10, 2008.
4. Goodnough LT. Erythropoietin therapy versus red cell transfusion. Curr Opin Hematol 2001; 8:405-410.
5. Bennett-Guerrero E, Veldman TH, Doctor A et al. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A 2007;104:17063-17068.
6. Leal-Noval SR, Jara-Ĺpez I. Garća-Garmendia JL et al. Influence of erythrocyte concentrate storage time on postsurgical morbidity in cardiac surgery patients. Anesthesiology 2003;98:815-822.
7. Purdy FR, Tweeddale MG, Merrick PM. Association of mortality withage of blood transfused in septic ICU patients. Can J Anaesth 1997;44:1256-1261.
8. Zallen G, Offner PJ, Moore EE et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg 1999;178:570-572.
9. Littlewood TJ, Bajetta E, Nortier J W et al. Effects of epoetinalfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
10. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.
11. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. NEngl J Med 1990;322:1693-1699.
12. Abels Rl. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992;87(suppl 1):4-11.
13. Henry DH. Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Clin North Am 1994;8:961-973.
14. O'Shaughnessy JA, Vukelja SJ, Holmes FA et al. Feasibility of quantifying the effects of epoetin alfa therapy oncognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005;5:439-446.
15. Harrison LB, Shasha D, White C et al. Radiotherapy-associated anemia: The scope of the problem. The Oncologist 2000:5(suppl 2): 1-7.
16. Vaupel P. Hypoxia and aggressive tumor phenotype: Implications for therapy and prognosis. The Oncologist 2008; 13(suppl 3):21-26.
17. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
18. Spano JP, Khayat D. Treatment options for anemia, taking risks into consideration: Erythropoiesis-stimulating agents versus transfusions. The Oncologist 2008;13(supp13):27-32.
19. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-5972.
20. Henke M, Laszig R, Ŕbe C et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
21. Danish Head and Neck Cancer Group. Interim Analysis of DAHANCA 10. Available at http://www.dahanca.dk/get_media_file.php?mediaid=125. Accessed September 21, 2007.
22. Wright JR, Ung YC, Julian JA et al. Randomized, double blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-1032.
23. Smith RE Jr. Aapro MS, Ludwig H et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-1050.
24. Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-4713.
25. Gasćn P. Safety update on erythropoiesis-stimulating agents: Trials within and outside the accepted indications. The Oncologist 2008:13(supp13):4-10.
26. Fandrey J. Erythropoietin receptors on tumor cells: What do they mean? The Oncologist 2008:13(supp13):16-20.
27. Dicato M. Venous thromboembolic events and ery thropoiesis-stimulating agents: An update. The Oncologist 2008;13(supp13):11-15.
28. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-270.
29. EMEA (European Medicines Agency). Post-authorisation Evaluation of Medicines for Human Use. Public Statement: Epoetins and the Risk of Tumour Growth Progression and Thromboembolic Events in Cancer Patients and Cardiovascular Risks in Patients With Chronic Kidney Disease. London, 23 October 2007. Available at http://www.emea.europa. eu/pdfs/human/press/pus/49618807en. pdf. Accessed April 10, 2008.